ARCHIVES

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

This article is from The Cancer Letter archive.

Vol. 06 No. 32 | August 8, 1980

Download PDF Visit The Full Archive

Related Articles

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

NCI To Ask HCFA to Launch Pilot Clinical Trials Program

March 22, 1996

Center Grant Review Tougher, Yarbro Insists

May 23, 1975

Report Urges NCI: No Unfunded Mandates for Cancer Centers

October 18, 1996

NCAB Committee Still Debating How To Encourage Surgical Oncology

April 26, 1985

NIH Plans Conference On DCIS Diagnosis, Management

July 17, 2009